From: The European challenges of funding orphan medicinal products
Austriac | Belgium | Bulgaria | Czech Republic | Hungary | Poland | Slovenia | |
---|---|---|---|---|---|---|---|
2013 | |||||||
Total public expenditures on OMPs (thousand €) | 98,600a | 245,000a | 8266a | 42,340a | 32,262a | 50,649a | 16,893a |
Total GDP (thousand €) | 322,539,200b | 391,712,000b | 42,011,500b | 157,741,600b | 101,483,300b | 394,721,100b | 35,917,100b |
Total public expenditures on OMPs in proportion of GDP (%) | 0.03% | 0.06% | 0.02% | 0.03% | 0.03% | 0.01% | 0.05% |
% of total pharmaceutical expenditures | 3.74% e | 6.18% f | 3.07% g | 2.00% h | 3.42% i | 1.95% j | 4.65% k |
% of total healthcare expenditures | NA | 0.91% f | NA | 0.4% h | 0.53% i | 0.34% j | 0.74% k |
Total pharmaceutical expenditures (thousand €) (calculated) | 2,636,364 | 3,964,401 | 269,248 | 2,117,013 | 943,332 | 2,597,381 | 363,297 |
Total healthcare expenditures (thousand €) (calculated) | NA | 26,923,077 | NA | 10,585,065 | 6,087,161 | 14,896,746 | 2,282,879 |
2014 | |||||||
Total public expenditures on OMPs (thousand €) (Growth compared to 2013, %) | 109,800 (+ 11.4%)a | 280,000 (+ 14.3%)a | 12,228 (+ 47.9%)a | 50,835 (+ 20.1%)a | 40,498 (+ 25.5%)a | 83,341 (+ 64.5%)a | 19,854 (+ 17.5%)a |
Total GDP (thousand €) | 330,417,600b | 400,805,000b | 42,762,200b | 166,964,100b | 104,953,300b | 410,989,700b | 37,332,400b |
Total public expenditures on OMPs in proportion of GDP (%) | 0.03% | 0.07% | 0.03% | 0.03% | 0.04% | 0.02% | 0.05% |
% of total pharmaceutical expenditures | 3.94%e | 6.84% f | 4.15% g | 2.50% h | 4.25% i | 3.2% j | 5.47% k |
% of total healthcare expenditures | NA | 1.01% f | NA | 0.60% h | 0.66% i | 0.54% j | 0.84% k |
Total pharmaceutical expenditures (thousand €) (calculated) | 2,786,802 | 4,093,567 | 294,654 | 2,033,406 | 952,883 | 2,604,432 | 362,956 |
Total healthcare expenditures (thousand €) (calculated) | NA | 27,722,772 | NA | 8,472,525 | 6,135,990 | 15,433,670 | 2,363,538 |
Total public expenditures on OMPs in proportion of GDP (%) in 2013 | 0.03% | 0.06% | 0.02% | 0.03% | 0.03% | 0.01% | 0.05% |
Total public expenditures on OMPs in proportion of GDP (%) in 2014 | 0.03% | 0.07% | 0.03% | 0.03% | 0.04% | 0.02% | 0.05% |
Average | 0.03% | 0.07% | 0.02% | 0.03% | 0.04% | 0.02% | 0.05% |
Total public expenditure on OMPs as a proportion of total public pharmaceutical expenditures in 2013 | 3.74% | 6.18% | 3.07% | 2.00% | 3.42% | 1.95% | 4.65% |
Total public expenditure on OMPs as a proportion of total public pharmaceutical expenditures in 2014 | 3.94% | 6.84% | 4.15% | 2.50%d | 4.25% | 3.20% | 5.47% |
Average | 3.84% | 6.51% | 3.61% | 2.25% | 3.84% | 2.58% | 5.06% |
Total public expenditure on OMPs as a proportion of total public healthcare expenditures in 2013 | NA | 0.91% | NA | 0.40% | 0.53% | 0.34% | 0.74% |
Total public expenditure on OMPs as a proportion of total public healthcare expenditures in 2014 | NA | 1.01% | NA | 0.60%d | 0.66% | 0.54% | 0.84% |
Average | NA | 0.96% | NA | 0.50% | 0.60% | 0.44% | 0.79% |